Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

One of the biotech's most promising candidates failed to earn FDA approval. Should investors jump ship?

Is Gilead Sciences a Buy After Its Most Recent Roadblock?

A study assessing Gilead Sciences Inc.'s GILD, -0.63% experimental drug remdesivir in moderately ill hospitalized COVID-19 patients found that a shorter 5-day course of treatment was more effective than a 10-day regimen when compared to the standard of care at that time.

Gilead's remdesivir may benefit moderately ill COVID-19 patients but findings 'uncertain'

The National Institutes Of Health is set to investigate a Gilead Sciences, Inc (NASDAQ: GILD) compound, similar to remdesivir, which could be effective against COVID-19, Stat reported Monday.

Gilead's Remdesivir-Like Compound To Be Studied By NIH For Efficacy Against COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.

Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020

Broadcom

Exelon

Kraft Heinz

NetApp

Walgreens

It took a pause Monday. Dividend investors should pay attention.

Who Said the Nasdaq Doesn't Have Dividend Stocks?

AstraZeneca

Johnson & Johnson

Pfizer

Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.

FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus

The Food and the Drug Administration (FDA) on Sunday issued an emergency use authorization (EUA) for convalescent plasma gathered from people who have recovered by COVID-19 as a treatment for hospitalized coronavirus patients.

FDA authorizes plasma treatment for COVID-19 patients

AbbVie

Market Neutral Strategy: Long AbbVie, Short Gilead

An Issue Presents A Buying Opportunity For Gilead

Biotech company Gilead gained the Food And Drug Administration's nod for its coronavirus treatment. Now, the company says remdesivir can lessen the risk of death.

Gilead Says Coronavirus Drug Lessens Death — But Is GILD Stock A Buy?

Gilead Sciences Fails At Filgotinib - What's Next?

Gilead Sciences said it will evaluate the U.S. Food and Drug Administration's request for more data on its rheumatoid arthritis drug, as GILD stock fell early Wednesday on the decision.

Gilead Sciences Disappointed By FDA Arthritis Drug Decision; GILD Stock Falls

Gilead Sciences, Inc. (NASDAQ: GILD) faces a regulatory setback as filgotinib,  an investigational drug it is co-developing with GALAPAGOS NV/S ADR (NASDAQ: GLPG), received a thumbs-down from the FDA.

Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling

Onlookers had been expecting a thumbs up for filgotinib. Now, that won't happen for at least another year.

FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug

Galapagos

When it rains, it pours. BioMarin Pharma was not the only company to receive a Complete Response Letter (CRL) from the U.S.

The FDA Comes Down on Gilead and Galapagos With CRL

Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

Shares of Gilead Sciences fell 3% after the U.S. Food and Drug Administration declined to approve its experimental rheumatoid arthritis treatment, a major setback for one of the drugmaker's important products.

Gilead shares slide after FDA knocks back rheumatoid arthritis drug

Gilead Sciences GILD, -0.13% investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S.

Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says

Gilead Sciences, Inc (NASDAQ: GILD) shares took a jolt in the after-hours session Tuesday as it announced its application for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA) didn’t get the go-ahead from the United States Food and Drug Administration.

Gilead's Rheumatoid Arthritis Drug Application Is A No-Go In Present Form: FDA

 Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).

Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis

Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis

Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.

Gilead Expands Collaboration With Tango for Cancer Therapies

Shares of Gilead Sciences Inc. GILD, +0.94% gained 0.3% in premarket trading on Tuesday after the drugmaker on Monday evening announced a deal worth more than $6 billion with Tango Therapeutics.

Gilead announces another cancer deal

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

The healthcare stock is down more than 10% in just the past month.

News for Gilead Sciences Stock (GILD)